Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in Moderate to Severe Hidradenitis Suppurativa
NCT07855276Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing LOU064 with Placebo (2 arms). Primary endpoint: Fold change from baseline in auto-antibodies at Week 16. Started Oct 2026; status: recruiting.
02
Drugs
remibrutinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07855276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07855276.